Efficacy of Posaconazole against Three Clinical Aspergillus fumigatus Isolates with Mutations in the cyp51A Gene
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The in vivo efficacy of posaconazole against 4 clinical Aspergillus fumigatus isolates with posaconazole MICs ranging from 0.03 to 16 mg/liter, as determined by CLSI method M38A, was assessed in a nonneutropenic murine model of disseminated aspergillosis. The underlying resistance mechanisms of the isolates included substitutions in the cyp51A gene at codon 220 (M220I), codon 54 (G54W), and codon 98 (L98H). The latter was combined with a 34-bp tandem repeat in the gene promoter region (TR L98H). The control isolate exhibited a wild-type phenotype without any known resistance mechanism. Oral posaconazole therapy was started 24 h after infection and was given once daily for 14 consecutive days. Mice were treated with four different doses (1 to 64 mg/kg of body weight), and survival was used as the end point. Survival was dependent both on the dose and on the MIC. The Hill equation with a variable slope fitted the relationship between the dose/MIC ratio and 14-day survival well ( R 2 , 0.92), with a 50% effective dose (ED 50 ) of 29.0 mg/kg (95% confidence interval [CI], 15.6 to 53.6 mg/kg). This also applied to the relationship between the area under the plasma concentration-time curve (AUC)/MIC ratio and 14-day survival (50% effective pharmacodynamic index [EI 50 ], 321.3 [95% CI, 222.7 to 463.4]). Near-maximum survival was reached at an AUC/MIC ratio of nearly 1,000. These results indicate that treatment of infections with A. fumigatus strains for which MICs are 0.5 mg/liter requires doses exceeding the present licensed doses. Increasing the standard dosing regimen may have some effect and may be clinically useful if no alternatives are available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307 · cited 1×
“Over recent years, Aspergillus fumigatus has become the most widespread opportunistic fungal pathogen, causing severe and commonly fatal invasive fungal infections in immunocompromised hosts (2, 4, 15).”
BackgroundAspergillus fumigatus and Aspergillosis in 2019
Latgé, J.-P., & Chamilos, G. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00140-18 · Cited by 1,400
Mellado, E., Garcia-Effron, G., Alcázar-Fuoli, L., Melchers, W. J. G., Verweij, P. E., Cuenca-Estrella, M., & Rodríguez-Tudela, J. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01092-06 · Cited by 490 · cited 13×
“We observed a 50% loss of efficacy in those isolates harboring cyp51A substitutions, i.e., the TR L98H and M220I substitutions, associated with a phenotype that increased the MIC of posaconazole by four 2-fold dilution steps, from 0.03 to 0.5 mg/liter.”
BackgroundSelf-citationMellado, E., Diaz-Guerra, T. M., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.7.2431-2438.2001 · Cited by 307 · cited 1×
“fumigatus, there are two distinct but related cyp51 proteins, encoded by cyp51A and cyp51B (18), respectively.”
BackgroundMellado, E., Garcia-Effron, G., Alcazar-Fuoli, L., Cuenca-Estrella, M., & Rodriguez-Tudela, J. L. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2747-2750.2004 · Cited by 210
Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis
Andes, D., Marchillo, K., Conklin, R., Krishna, G., Ezzet, F., Cacciapuoti, A., & Loebenberg, D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.1.137-142.2004 · Cited by 177 · cited 4×
“In addition, the quantitative relationship between exposure and effect is comparable to that found for Candida strains (1).”
BackgroundResultInfluential
Cited by
Ullmann, A. J., Aguado, J. M., Arikan-Akdagli, S., Denning, D. W., Groll, A. H., Lagrou, K., Lass-Flörl, C., Lewis, R. E., Munoz, P., Verweij, P. E., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.01.002 · Cited by 1,556
Self-citationAshbee, H. R., Barnes, R. A., Johnson, E. M., Richardson, M. D., Gorton, R., & Hope, W. W. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt508 · Cited by 716
Clinical Implications of Azole Resistance in Aspergillus fumigatus, the Netherlands, 2007–2009
van der Linden, J. W. M., Snelders, E., Kampinga, G. A., Rijnders, B. J. A., Mattsson, E., Debets-Ossenkopp, Y. J., Kuijper, E. J., Van Tiel, F. H., Melchers, W. J. G., & Verweij, P. E. (2011) · Emerging Infectious Diseases · doi:10.3201/eid1710.110226 · Cited by 446
Self-citationPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Triazole Antifungal Agents in Invasive Fungal Infections: A Comparative Review
Lass-Flörl, C. (2011) · Drugs · doi:10.2165/11596540-000000000-00000 · Cited by 270
Azole-resistance in Aspergillus: Proposed nomenclature and breakpoints
Verweij, P. E., Howard, S. J., Melchers, W. J. G., & Denning, D. W. (2009) · Drug Resistance Updates · doi:10.1016/j.drup.2009.09.002 · Cited by 260
Self-citationTriazole resistance surveillance in Aspergillus fumigatus
Resendiz Sharpe, A., Lagrou, K., Meis, J. F., Chowdhary, A., Lockhart, S. R., Verweij, P. E., & on behalf of the ISHAM/ECMM Aspergillus Resistance Surveillance working group (2018) · Medical Mycology · doi:10.1093/mmy/myx144 · Cited by 150
Self-citationAntifungal Pharmacokinetics and Pharmacodynamics
Lepak, A. J., & Andes, D. R. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019653 · Cited by 134
“The PD target free-drug AUC/MIC for Aspergillus associated with either ED50 or net stasis targets was only 1.7–11 (Mavridou et al. 2010a,b; Howard et al. 2011; Lepak et al. 2013a,c).”
BackgroundResultInfluentialArendrup, M. C., Cuenca-Estrella, M., Lass-Flörl, C., & Hope, W. W. (2013) · Drug Resistance Updates · doi:10.1016/j.drup.2014.01.001 · Cited by 129
“Since the interaction between the invading organism and the antifungal agent is largely independent of the host, the magnitude of the PKPD index that is associated with a favourable outcome in one context (experimental of clinical) may also be applicable to another (Howard et al., 2011a; Mavridou et al., 2010; Walsh e…”
BackgroundMethodDudakova, A., Spiess, B., Tangwattanachuleeporn, M., Sasse, C., Buchheidt, D., Weig, M., Groß, U., & Bader, O. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00095-16 · Cited by 113
Verweij, P. E., Kema, G. H., Zwaan, B., & Melchers, W. J. (2013) · Pest Management Science · doi:10.1002/ps.3390 · Cited by 67
Self-citationKrishnan Natesan, S., Wu, W., Cutright, J. L., & Chandrasekar, P. H. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.06.030 · Cited by 58
“Data on clinical azole cross-resistance are still evolving (Bellete et al., 2010; Mavridou et al., 2010; Thors et al., 2011).”
BackgroundDesoubeaux, G., & Cray, C. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00841 · Cited by 55
“…on theA. fumigatus strain(s) selected (Johnson et al., 2000; Takemoto et al., 2004, 2006; Cacciapuoti et al., 2006; Warn et al., 2006, 2010; Mavridou et al., 2010a,b), the aims of the study [e.g., Gao et al., doubled the inoculum when studying histopathology (Gao et al., 1997), whereas…”
BackgroundMethodSeyedmousavi, S., Meletiadis, J., Melchers, W. J. G., Rijs, A. J. M. M., Mouton, J. W., & Verweij, P. E. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00980-12 · Cited by 38
“These clinical observations are supported by preclinical studies in animal models of IA (5, 11, 13–19), where the MIC was shown to have a major impact on the efficacy of voriconazole and posaconazole (15, 20).”
ResultSelf-citationAnimal Models for Studying Triazole Resistance in Aspergillus fumigatus
Lewis, R. E., & Verweij, P. E. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix222 · Cited by 13
Self-citation
Metadata
- Authors
- Mavridou, E., Brüggemann, R. J. M., Melchers, W. J. G., Mouton, J. W., & Verweij, P. E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2010-02
- Volume
- 54
- Issue
- 2
- Pages
- 860-865
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2170688673
- Cited by
- 112
- References
- 6
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.